IXHL Incannex Healthcare Limited
USHealthcareAs of 2026-07-09 15:55
Why IXHL matters now
Incannex Healthcare Limited (IXHL) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.34 with -1.33% on the session and $39.9M in market capitalization; recent performance reads 1-month -3.78% and YTD -66.85%.
The latest financial table shown here is Q3 2026, with revenue of $0.00, net income of $-3.9M, and EPS of $-0.35. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -31.5%.
The latest indexable market news headline is "Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.58
P/S
639.39
EV/EBITDA
0.60
DCF Value
$8.40
FCF Yield
-31.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-192.7%
Operating Margin
-52287.7%
Net Margin
-74973.0%
ROE
-122.6%
ROA
-62.2%
ROIC
-44.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-3.9M | $-0.35 |
| Q2 2026 | $0.00 | $-6.5M | $-0.60 |
| Q4 2025 | $66.6K | $-35.6M | $-0.69 |
| FY 2025 | $86.0K | $-46.9M | $-40.80 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
AU
Exchange
—
Beta
2.84
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.